The C5 inhibitor, recently acquired by Astellas, will be commercially available in two to four weeks and will compete against Apellis Pharma’s Syfovre.

Daiichi Sankyo, Chugai and Shionogi all marked double-digit revenue growth in the fiscal first quarter, while Astellas and Takeda saw some slow down. New products including Veozah and Leqembi buoyed performances, while the the expected upcoming US approval of a subcutaneous formulation may help restore Entyvio’s growth trajectory.

Second quarter sales of the new geographic atrophy drug exceeded expectations, but the company confirmed seven events of retinal vasculitis in patients treated with Syfovre in the real world.

The US biotech’s ANX007 has some analysts cautiously optimistic as post hoc Phase II analyses backed its ability to improve visual acuity in geographic atrophy secondary to age-related macular edema despite a prior primary endpoint miss.